Austco Healthcare (AHC) Q4 2025 TU earnings summary

Executive summary

• Achieved over 37% year-over-year revenue growth and over 54% EBITDA growth for FY25, driven by both organic performance and strategic acquisitions.

• Successfully integrated Amentco and G&S Technologies, with Amentco outperforming expectations and G&S acquisition fully funded from operating cash flows.

• Maintained a strong balance sheet, increasing cash position to $14.4 million while funding acquisitions.

Financial highlights

• FY25 unaudited revenue projected at $80–$82 million, up from $58.2 million in FY24 (37% increase).

• EBITDA expected at $12.5–$13.5 million, up from $8.1 million in FY24 (54–67% increase).

• Cash at bank rose to $14.4 million, a 6% increase year-over-year.

• Unfilled contracted revenue reached $55.8 million, up from $50.2 million in February 2025.

Outlook and guidance

• Entering FY26 with robust contracted revenue and positive momentum across key markets.

• Confident outlook supported by strong operational performance and scalable business model.

• Audited full year results and Appendix 4E to be released on 26 August 2025.